title: [New perspectives in the treatment of diabetes by interfering with glucagon signaling pathway].
abstract: Glucagon, a hormone secreted from the alpha cell of the endocrine pancreas, is a major counterpart to insulin. After released into blood, glucagon will combine with its receptor in targeting tissues and form a compound, which then activates its signaling pathway, produces cAMP, promotes gluconeogenesis and glycogenolysis and inventually increases blood glucose. Researches recently display that it will be an important addition to treatment method by inhibiting synthesis and secretion of glucagon, neutralizing circulating glucagon, using glucagon receptor antagonists and prohibiting gene expression of glucagon receptor.
authors: Department of Endocrinology and Metabolism, West china Hospital of Sichuan University, Chengdu 610041, China.
authors: Jin-jin
authors: JJ
authors: Gu
authors: Tie-yun
authors: TY
authors: Zhao
authors: Xiu-jun
authors: XJ
authors: Li
mesh_terms: D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D003920:Diabetes Mellitus / Q000473:pathology / Q000628:therapy*; D005934:Glucagon / Q000378:metabolism / Q000502:physiology*; D005943:Gluconeogenesis / Q000502:physiology; D050261:Glycogenolysis / Q000502:physiology; D006801:Humans; D018027:Receptors, Glucagon / Q000037:antagonists & inhibitors* / Q000502:physiology; D015398:Signal Transduction / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D018027:Receptors, Glucagon; D005934:Glucagon